{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T05:40:07Z","timestamp":1756532407171,"version":"3.44.0"},"reference-count":65,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2025-0265_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the characteristics of an immunochemical urinary free light chains (uFLC) test in screening and quantifying Bence Jones proteinuria (BJP) and its potential application in laboratory practice as an alternative to the gold standard method, urine immunofixation (UIFE) and densitometric quantification on 24 h urine sample.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2025-0265_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 300 subjects were divided into five groups: controls, patients with BJP Kappa and Lambda present in trace amounts not densitometrically quantifiable, and patients with BJP Kappa and Lambda present in densitometrically measurable quantities. The Wilcoxon-Mann-Whitney test was applied to compare uFLC in controls and BJP trace samples. The correlation between immunochemical and densitometric measurements was assessed using Spearman\u2019s correlation coefficient, and agreement was evaluated with Bland-Altman plots. Samples were also stratified by estimated glomerular filtration rate (eGFR) and total urinary proteins (TUP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2025-0265_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Despite significant differences between the median values of uFLC measures in controls and BJP in trace sample groups, using the uFLC upper reference ranges would have led to over 50\u202f% false negative results. Although a strong correlation existed between the two methods, turbidimetry consistently overestimated BJP levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2025-0265_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>uFLC turbidimetric measurements cannot accurately differentiate negative samples from those containing trace BJP, lacking the sensitivity required for clinical use. UIFE has shown greater sensitivity compared to turbidimetry. In monitoring, the systematic overestimation in the quantification of BJP, aggravated in cases of reduced renal function or high TUP concentration, makes it challenging for clinicians to evaluate therapeutic efficacy since the decision thresholds outlined in clinical guidelines are based on densitometric measurements.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2025-0265","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T16:14:48Z","timestamp":1748794488000},"page":"2031-2042","source":"Crossref","is-referenced-by-count":0,"title":["Immunochemical measurement of urinary free light chains and Bence Jones proteinuria"],"prefix":"10.1515","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0915-6488","authenticated-orcid":false,"given":"Laura","family":"Michetti","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine , Clinical Pathology Laboratory, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1 , Bergamo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5392-3570","authenticated-orcid":false,"given":"Rudi","family":"Ravasio","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Clinical Pathology Laboratory, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1 , Bergamo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0031-4170","authenticated-orcid":false,"given":"Roberto","family":"Marozzi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Clinical Pathology Laboratory, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1 , Bergamo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0685-4827","authenticated-orcid":false,"given":"Ester","family":"Antelmi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Clinical Pathology Laboratory, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1 , Bergamo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9391-6963","authenticated-orcid":false,"given":"Arianna","family":"Ghirardi","sequence":"additional","affiliation":[{"name":"FROM Research Foundation , ASST Papa Giovanni XXIII Hospital Piazza OMS, 1 , Bergamo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1542-0582","authenticated-orcid":false,"given":"Greta","family":"Bolzoni","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Clinical Pathology Laboratory, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1 , Bergamo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2025083005004168804_j_cclm-2025-0265_ref_001","doi-asserted-by":"crossref","unstructured":"Xu, ZL, Wu, C, Teng, WH, Wan, K, Jia, WJ, Li, HJ, et al.. Exploring the relationship between serum and urinary free light chain levels during the different phases of renal damage in multiple myeloma patients. Indian J Hematol Blood Transfus 2015;31:352\u20135. https:\/\/doi.org\/10.1007\/s12288-014-0480-3.","DOI":"10.1007\/s12288-014-0480-3"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_002","doi-asserted-by":"crossref","unstructured":"Rana, R, Cockwell, P, Drayson, M, Cook, M, Pratt, G, Cairns, DA, et al.. Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Adv 2020;4:5836\u201345. https:\/\/doi.org\/10.1182\/bloodadvances.2020002872.","DOI":"10.1182\/bloodadvances.2020002872"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_003","unstructured":"Basset, M, Milani, P, Bosoni, T, Nuvolone, M, Albertini, R, Merlini, G, et al.. Proteinuria e albuminuria nelle discrasie plasmacellulari. Biochim Clin 2023;47:S76\u201384."},{"key":"2025083005004168804_j_cclm-2025-0265_ref_004","doi-asserted-by":"crossref","unstructured":"Hutchison, CA, Batuman, V, Behrens, J, Bridoux, F, Sirac, C, Dispenzieri, A, et al.. On behalf of the International Kidney and Monoclonal Gammopathy Research Group. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2012;8:43\u201351. https:\/\/doi.org\/10.1038\/nrneph.2011.168.","DOI":"10.1038\/nrneph.2011.168"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_005","doi-asserted-by":"crossref","unstructured":"Landgren, O, Rajkumar, SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res 2016;22:5428\u201333. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-0866.","DOI":"10.1158\/1078-0432.CCR-16-0866"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_006","doi-asserted-by":"crossref","unstructured":"Rajkumar, SV. Evolving diagnostic criteria for multiple myeloma. Hematology 2015;2015:272\u20138. https:\/\/doi.org\/10.1182\/asheducation-2015.1.272.","DOI":"10.1182\/asheducation-2015.1.272"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_007","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Calle, V, D\u00e1vila, J, Escalante, F, De Coca, AG, Aguilera, C, L\u00f3pez, R, et al.. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia 2016;30:2026\u201331. https:\/\/doi.org\/10.1038\/leu.2016.123.","DOI":"10.1038\/leu.2016.123"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_008","doi-asserted-by":"crossref","unstructured":"Kyle, RA, Remstein, ED, Therneau, TM, Dispenzieri, A, Kurtin, PJ, Hodnefield, JM, et al.. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N\u00a0Engl J Med 2007;356:2582\u201390. https:\/\/doi.org\/10.1056\/nejmoa070389.","DOI":"10.1056\/NEJMoa070389"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_009","doi-asserted-by":"crossref","unstructured":"Parmar, MS. (F)utility of urine Bence Jones proteins for \u201croutine\u201d screening for plasma cell dyscrasia. Diagnosis 2021;8:439\u201343. https:\/\/doi.org\/10.1515\/dx-2020-0104.","DOI":"10.1515\/dx-2020-0104"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_010","doi-asserted-by":"crossref","unstructured":"Durie, BGM, Harousseau, JL, Miguel, JS, Blad\u00e9, J, Barlogie, B, Anderson, K, et al.. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467\u201373. https:\/\/doi.org\/10.1038\/sj.leu.2404284.","DOI":"10.1038\/sj.leu.2404284"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_011","doi-asserted-by":"crossref","unstructured":"Rajkumar, SV, Buadi, F. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol 2007;20:665\u201380. https:\/\/doi.org\/10.1016\/j.beha.2007.10.002.","DOI":"10.1016\/j.beha.2007.10.002"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_012","doi-asserted-by":"crossref","unstructured":"Palladini, G, Dispenzieri, A, Gertz, MA, Kumar, S, Wechalekar, A, Hawkins, PN, et al.. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J\u00a0Clin Oncol 2012;30:4541\u20139. https:\/\/doi.org\/10.1200\/jco.2011.37.7614.","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_013","doi-asserted-by":"crossref","unstructured":"Bird, J, Behrens, J, Westin, J, Turesson, I, Drayson, M, Beetham, R, et al.. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009;147:22\u201342. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07807.x.","DOI":"10.1111\/j.1365-2141.2009.07807.x"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_014","doi-asserted-by":"crossref","unstructured":"Van De Donk, NWCJ, Palumbo, A, Johnsen, HE, Engelhardt, M, Gay, F, Gregersen, H, et al.. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica 2014;99:984\u201396. https:\/\/doi.org\/10.3324\/haematol.2013.100552.","DOI":"10.3324\/haematol.2013.100552"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_015","doi-asserted-by":"crossref","unstructured":"Kyle, RA, Durie, BGM, Rajkumar, SV, Landgren, O, Blade, J, Merlini, G, et al.. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121\u20137. https:\/\/doi.org\/10.1038\/leu.2010.60.","DOI":"10.1038\/leu.2010.60"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_016","doi-asserted-by":"crossref","unstructured":"Dimopoulos, M, Kyle, R, Fermand, JP, Rajkumar, SV, San Miguel, J, Chanan-Khan, A, et al.. Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood 2011;117:4701\u20135. https:\/\/doi.org\/10.1182\/blood-2010-10-299529.","DOI":"10.1182\/blood-2010-10-299529"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_017","doi-asserted-by":"crossref","unstructured":"Tate, J, Caldwell, G, Daly, J, Gillis, D, Jenkins, M, Jovanovich, S, et al.. Recommendations for standardized reporting of protein electrophoresis in Australia and New\u00a0Zealand. Ann Clin Biochem Int J Lab Med 2012;49:242\u201356. https:\/\/doi.org\/10.1258\/acb.2011.011158.","DOI":"10.1258\/acb.2011.011158"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_018","unstructured":"Natali, P, Cigliana, G, Savoia, M, Gelsumini, S, Basile, U, Vernocchi, A, et al.. Revisione e aggiornamento del documento di consenso SIBioC per la ricerca e quantificazione della proteina di Bence Jones. Biochim Clin 2020;45:75\u201386."},{"key":"2025083005004168804_j_cclm-2025-0265_ref_019","unstructured":"Ramakrishnan, N, Jialal, I. Bence-Jones protein. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025."},{"key":"2025083005004168804_j_cclm-2025-0265_ref_020","doi-asserted-by":"crossref","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749\u201357. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04355.x.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_021","doi-asserted-by":"crossref","unstructured":"Kyle, RA. Sequence of testing for monoclonal gammopathies. Arch Pathol Lab Med 1999;123:114\u20138. https:\/\/doi.org\/10.5858\/1999-123-0114-sotfmg.","DOI":"10.5858\/1999-123-0114-SOTFMG"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_022","unstructured":"Katzmann, JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 2009;30:105\u201311."},{"key":"2025083005004168804_j_cclm-2025-0265_ref_023","doi-asserted-by":"crossref","unstructured":"Singh, G. Serum and urine protein electrophoresis and serum-free light chain assays in the diagnosis and monitoring of monoclonal gammopathies. J\u00a0Appl Lab Med 2020;5:1358\u201371. https:\/\/doi.org\/10.1093\/jalm\/jfaa153.","DOI":"10.1093\/jalm\/jfaa153"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_024","doi-asserted-by":"crossref","unstructured":"Bird, JM, Owen, RG, D\u2019Sa, S, Snowden, JA, Pratt, G, Ashcroft, J, et al.. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011;154:32\u201375. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08573.x.","DOI":"10.1111\/j.1365-2141.2011.08573.x"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_025","doi-asserted-by":"crossref","unstructured":"Graziani, M, Merlini, G, Petrini, C, IFCC Committee on Plasma Proteins; SIBioC Study Group on Proteins. Guidelines for the analysis of bence Jones protein. Clin Chem Lab Med 2003;41:338\u201346. https:\/\/doi.org\/10.1515\/cclm.2003.054.","DOI":"10.1515\/CCLM.2003.054"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_026","doi-asserted-by":"crossref","unstructured":"Roden, AC, Lockington, KS, Tostrud, LJ, Katzmann, JA. Urine protein electrophoresis and immunoelectrophoresis using unconcentrated or minimally concentrated urine samples. Am J Clin Pathol 2008;130:141\u20135. https:\/\/doi.org\/10.1309\/6k33ktfa7a5vuq1t.","DOI":"10.1309\/6K33KTFA7A5VUQ1T"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_027","doi-asserted-by":"crossref","unstructured":"Beetham, R. Detection of Bence-Jones protein in practice. Ann Clin Biochem Int J Lab Med 2000;37:563\u201370. https:\/\/doi.org\/10.1258\/0004563001899690.","DOI":"10.1258\/0004563001899690"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_028","doi-asserted-by":"crossref","unstructured":"Salomo, M, Gimsing, P, Nielsen, LB. Simple method for quantification of Bence Jones proteins. Clin Chem 2002;48:2202\u20137. https:\/\/doi.org\/10.1093\/clinchem\/48.12.2202.","DOI":"10.1093\/clinchem\/48.12.2202"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_029","doi-asserted-by":"crossref","unstructured":"Mikhael, J. Pee no more? Urine light chains down the drain. Blood 2016;128:2873\u20134. https:\/\/doi.org\/10.1182\/blood-2016-10-746883.","DOI":"10.1182\/blood-2016-10-746883"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_030","doi-asserted-by":"crossref","unstructured":"Dejoie, T, Corre, J, Caillon, H, Moreau, P, Attal, M, Loiseau, HA. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia 2019;33:313\u20138. https:\/\/doi.org\/10.1038\/s41375-018-0339-y.","DOI":"10.1038\/s41375-018-0339-y"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_031","doi-asserted-by":"crossref","unstructured":"Natsuhara, KH, Huang, CY, Knoche, J, Arora, S, Chung, A, Martin, T, et al.. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma. Leuk Lymphoma 2023;64:1186\u201393. https:\/\/doi.org\/10.1080\/10428194.2023.2201365.","DOI":"10.1080\/10428194.2023.2201365"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_032","unstructured":"Natali, P, Cigliana, G, Napodano, C, Basile, V, Debbia, D, Pocino, K, et al.. The dark side of current analytic methods for Bence Jones Proteinuria. Eur Rev Med Pharmacol Sci 2022;26:6777\u201386. https:\/\/doi.org\/10.26355\/eurrev_202209_29779."},{"key":"2025083005004168804_j_cclm-2025-0265_ref_033","doi-asserted-by":"crossref","unstructured":"Pieri, M, De Stefano, A, Franceschini, L, Rizzo, M, Duranti, F, Bernardini, S, et al.. Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry? Br J Haematol 2016;175:733\u20135. https:\/\/doi.org\/10.1111\/bjh.13878.","DOI":"10.1111\/bjh.13878"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_034","doi-asserted-by":"crossref","unstructured":"Le Bricon, T, Bengoufa, D, Benlakehal, M, Bousquet, B, Erlich, D. Urinary free light chain analysis by the Freelite\u00ae immunoassay: a preliminary study in multiple myeloma. Clin Biochem 2002;35:565\u20137. https:\/\/doi.org\/10.1016\/s0009-9120(02)00386-7.","DOI":"10.1016\/S0009-9120(02)00386-7"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_035","doi-asserted-by":"crossref","unstructured":"Sarto, C, Intra, J, Fania, C, Brivio, R, Brambilla, P, Leoni, V. Monoclonal free light chain detection and quantification: performances and limits of available laboratory assays. Clin Biochem 2021;95:28\u201333. https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.05.006.","DOI":"10.1016\/j.clinbiochem.2021.05.006"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_036","doi-asserted-by":"crossref","unstructured":"Snyder, MR, Clark, R, Bryant, SC, Katzmann, JA. Quantification of urinary light chains. Clin Chem 2008;54:1744\u20136. https:\/\/doi.org\/10.1373\/clinchem.2008.107599.","DOI":"10.1373\/clinchem.2008.107599"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_037","doi-asserted-by":"crossref","unstructured":"Graziani, MS, Merlini, G. Measurement of free light chains in urine. Clin Chem 2001;47:2069\u201370. https:\/\/doi.org\/10.1093\/clinchem\/47.11.2069.","DOI":"10.1093\/clinchem\/47.11.2069"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_038","doi-asserted-by":"crossref","unstructured":"Fenton, A, Jesky, MD, Webster, R, Stringer, SJ, Yadav, P, Chapple, I, et al.. Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease. PLoS One 2018;13:e0197043. https:\/\/doi.org\/10.1371\/journal.pone.0197043.","DOI":"10.1371\/journal.pone.0197043"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_039","doi-asserted-by":"crossref","unstructured":"Singh, G, Cotter, T, Ye Mon, M, Xu, H, Bollag, RJ. Quantification of free immunoglobulin light chains in urine. J\u00a0Appl Lab Med 2023;8:1101\u201314. https:\/\/doi.org\/10.1093\/jalm\/jfad055.","DOI":"10.1093\/jalm\/jfad055"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_040","doi-asserted-by":"crossref","unstructured":"Tate, JR, Mollee, P. Response to Letter to the Editor about immunochemical measurement of urine free light chains. Clin Chem Lab Med 2018;57:e3\u20134. https:\/\/doi.org\/10.1515\/cclm-2018-1082.","DOI":"10.1515\/cclm-2018-1082"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_041","doi-asserted-by":"crossref","unstructured":"Maisnar, V, Tichy, M, Stulik, J, Vavrova, J, Friedecky, B, Palicka, V, et al.. The problems of proteinuria measurement in urine with presence of Bence Jones protein. Clin Biochem 2011;44:403\u20135. https:\/\/doi.org\/10.1016\/j.clinbiochem.2011.01.008.","DOI":"10.1016\/j.clinbiochem.2011.01.008"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_042","doi-asserted-by":"crossref","unstructured":"Giussani, M, Ciniselli, CM, Macciotta, A, Panella, R, Verderio, P, Bonini, C, et al.. \u03ba and \u03bb urine free light chains: a new method for quantification. Tumori J 2020;106:457\u201363. https:\/\/doi.org\/10.1177\/0300891619898533.","DOI":"10.1177\/0300891619898533"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_043","doi-asserted-by":"crossref","unstructured":"Herzum, I, Renz, H, Wahl, HG. Immunochemical quantification of free light chains in urine. Clin Chem 2005;51:1033\u20135. https:\/\/doi.org\/10.1373\/clinchem.2004.045435.","DOI":"10.1373\/clinchem.2004.045435"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_044","unstructured":"Natali, P, Debbia, D, Cucinelli, MR, Nasillo, V, Riva, G, Cigliana, G, et al.. A new challenge for urinary free light chains: assessment of the upper reference limit in healthy subjects. Eur Rev Med Pharmacol Sci 2023;27:8915\u201323. https:\/\/doi.org\/10.26355\/eurrev_202309_33812."},{"key":"2025083005004168804_j_cclm-2025-0265_ref_045","doi-asserted-by":"crossref","unstructured":"Pieri, M, Pignalosa, S, Franceschini, L, Rizzo, M, Cantonetti, M, Zenobi, R, et al.. Nephelometric assay of urine free light chains: an alternative and early clinical test for Bence-Jones protein quantification. Clin Chem Lab Med 2018;56:e313\u201315. https:\/\/doi.org\/10.1515\/cclm-2018-0402.","DOI":"10.1515\/cclm-2018-0402"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_046","doi-asserted-by":"crossref","unstructured":"Delgado, JC. Value of urinary free light chain testing for monitoring of Bence-Jones proteinuria. J\u00a0Appl Lab Med 2019;3:1059\u201360. https:\/\/doi.org\/10.1373\/jalm.2018.027862.","DOI":"10.1373\/jalm.2018.027862"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_047","doi-asserted-by":"crossref","unstructured":"Levey, AS, Stevens, LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55:622\u20137. https:\/\/doi.org\/10.1053\/j.ajkd.2010.02.337.","DOI":"10.1053\/j.ajkd.2010.02.337"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_048","doi-asserted-by":"crossref","unstructured":"Wadhera, RK, Rajkumar, SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc 2010;85:933\u201342. https:\/\/doi.org\/10.4065\/mcp.2010.0337.","DOI":"10.4065\/mcp.2010.0337"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_049","doi-asserted-by":"crossref","unstructured":"Therneau, TM, Kyle, RA, Melton, LJ, Larson, DR, Benson, JT, Colby, CL, et al.. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc 2012;87:1071\u20139. https:\/\/doi.org\/10.1016\/j.mayocp.2012.06.014.","DOI":"10.1016\/j.mayocp.2012.06.014"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_050","unstructured":"CLSI. Defining, establishing, and verifying reference intervals in\u00a0the\u00a0clinical laboratory; Approved Guideline\u00a0\u2013\u00a0Third Edition. CLSI EPC28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2010."},{"key":"2025083005004168804_j_cclm-2025-0265_ref_051","doi-asserted-by":"crossref","unstructured":"Nowrousian, MR, Brandhorst, D, Sammet, C, Kellert, M, Daniels, R, Schuett, P, et al.. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005;11:8706\u201314. https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-0486.","DOI":"10.1158\/1078-0432.CCR-05-0486"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_052","doi-asserted-by":"crossref","unstructured":"Nakano, T, Nagata, A, Takahashi, H. Ratio of urinary free immunoglobulin light chain kappa to lambda in the diagnosis of Bence Jones proteinuria. Clin Chem Lab Med 2004;42:429\u201334. https:\/\/doi.org\/10.1515\/cclm.2004.075.","DOI":"10.1515\/CCLM.2004.075"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_053","doi-asserted-by":"crossref","unstructured":"Hutchison, CA, Harding, S, Hewins, P, Mead, GP, Townsend, J, Bradwell, AR, et al.. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:1684\u201390. https:\/\/doi.org\/10.2215\/cjn.02290508.","DOI":"10.2215\/CJN.02290508"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_054","doi-asserted-by":"crossref","unstructured":"Schmidt-Hieltjes, Y, Elshof, C, Roovers, L, Ruinemans-Koerts, J. Diagnostic reference range of \u03ba\/\u03bb free light chain ratio to screen for Bence Jones proteinuria is not significantly influenced by GFR. Eur J Haematol 2016;96:527\u201331. https:\/\/doi.org\/10.1111\/ejh.12632.","DOI":"10.1111\/ejh.12632"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_055","doi-asserted-by":"crossref","unstructured":"Graziani, MS, Merlini, G. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. Expert Rev Mol Diagn 2014;14:55\u201366. https:\/\/doi.org\/10.1586\/14737159.2014.864557.","DOI":"10.1586\/14737159.2014.864557"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_056","doi-asserted-by":"crossref","unstructured":"Keren, DF, Bocsi, G, Billman, BL, Etzell, J, Faix, JD, Kumar, S, et al.. Laboratory detection and initial diagnosis of monoclonal gammopathies. Arch Pathol Lab Med 2022;146:575\u201390. https:\/\/doi.org\/10.5858\/arpa.2020-0794-cp.","DOI":"10.5858\/arpa.2020-0794-CP"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_057","unstructured":"Natali, P, Patelli, G, Tagliavini, S, Carra, D, Cucinelli, MR, Varani, M, et al.. Accuratezza dell\u2019immunonefelometria come metodo di screening per la determinazione della proteinuria di Bence Jones. Biochim Clin 2017;41:148\u201353."},{"key":"2025083005004168804_j_cclm-2025-0265_ref_058","unstructured":"Merlini, G. Perch\u00e9 \u00e8 importante identificare e segnalare le piccole componenti monoclonali. Biochim Clin 2012;36:25\u20138."},{"key":"2025083005004168804_j_cclm-2025-0265_ref_059","doi-asserted-by":"crossref","unstructured":"Garc\u00eda Moreira, V, Cepeda Piorno, J, Sanders Vegara, J, Eyo Gonz\u00e1lez, A, Alberdi Garc\u00eda Del Castillo, C, Gonz\u00e1lez Garc\u00eda, C, et al.. Novel approach to rule-out unnecessary urine Bence Jones protein testing: a serum free light chain algorithm. Diagnostics 2025;15:525\u201340. https:\/\/doi.org\/10.3390\/diagnostics15050525.","DOI":"10.3390\/diagnostics15050525"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_060","doi-asserted-by":"crossref","unstructured":"Dispenzieri, A, Kyle, R, Merlini, G, Miguel, JS, Ludwig, H, Hajek, R, et al.. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215\u201324. https:\/\/doi.org\/10.1038\/leu.2008.307.","DOI":"10.1038\/leu.2008.307"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_061","doi-asserted-by":"crossref","unstructured":"Tate, JR, Gill, D, Cobcroft, R, Hickman, PE. Practical considerations for the measurement of free light chains in serum. Clin Chem 2003;49:1252\u20137. https:\/\/doi.org\/10.1373\/49.8.1252.","DOI":"10.1373\/49.8.1252"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_062","doi-asserted-by":"crossref","unstructured":"Xu, L, Zhao, B, Sun, Y, Wang, S, Chen, X, Mao, Y. Using two detection methods to observe the changes and significance of free light chain in serum and urine in patients with renal insufficiency. Formanowicz D, curatore. BioMed Res Int 2022;2022:1\u20136. https:\/\/doi.org\/10.1155\/2022\/5536199.","DOI":"10.1155\/2022\/5536199"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_063","doi-asserted-by":"crossref","unstructured":"Kyle, RA, Rajkumar, SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3\u20139. https:\/\/doi.org\/10.1038\/leu.2008.291.","DOI":"10.1038\/leu.2008.291"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_064","doi-asserted-by":"crossref","unstructured":"Kumar, S, Paiva, B, Anderson, KC, Durie, B, Landgren, O, Moreau, P, et al.. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328\u201346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"2025083005004168804_j_cclm-2025-0265_ref_065","doi-asserted-by":"crossref","unstructured":"Levinson, W, Kallewaard, M, Bhatia, RS, Wolfson, D, Shortt, S, Kerr, EA. \u2018Choosing Wisely\u2019: a growing international campaign. BMJ Qual Saf 2015;24:167\u201374. https:\/\/doi.org\/10.1136\/bmjqs-2014-003821.","DOI":"10.1136\/bmjqs-2014-003821"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0265\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0265\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T05:02:08Z","timestamp":1756530128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0265\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":65,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5,22]]},"published-print":{"date-parts":[[2025,9,25]]}},"alternative-id":["10.1515\/cclm-2025-0265"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0265","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"type":"print","value":"1434-6621"},{"type":"electronic","value":"1437-4331"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}